Pfizer
NEWS
The State of California is considering a measure to sell its own brand of generic drugs in an effort to get in on those cost-savings. California’s Gov. Gavin Newsom is expected to reveal the scheme today in his new state budget.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
Pfizer and Effector Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E.
“Bavencio is the first immunotherapy to demonstrate in a clinical trial a statistically significant improvement in overall survival as a first-line treatment for patients with advanced urothelial carcinoma,” said Chris Boshoff, chief development officer, Oncology, Pfizer Global Product Development.
According to an analysis conducted on Jan. 1, more than 250 drugs manufactured by different companies saw price increases.
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
Pfizer handed over $10 million in upfront money and dangled a potential $240 million more if the program hits certain development and sales milestones.
Pharma, biotech and life sciences organizations strengthen their leadership teams and boards.
With the latest approval, Xtandi, an androgen receptor inhibitor, is now the only oral treatment approved by the FDA for three distinct types of advanced prostate cancer – non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mCSPC.
JOBS
IN THE PRESS